How is CJC-1295 (no DAC) administered?
This describes how CJC-1295 (no DAC) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a 1-3x daily, paired with Ipamorelin schedule, generally over 8-12 weeks on, 4 weeks off. Specific dosing is individual and beyond general information, and human evidence for CJC-1295 (no DAC) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: 1-3x daily, paired with Ipamorelin
- Cycle length: 8-12 weeks on, 4 weeks off
- Half-life: ~30 min (no DAC)
References
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295 — Teichman SL et al., JCEM, 2006
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Jetté L et al., Endocrinology, 2005
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — Villegas Meza AD et al., JBJS Reviews, 2026
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on CJC-1295 (no DAC)
Full CJC-1295 (no DAC) breakdownCJC-1295 (no DAC) what it's used forCJC-1295 (no DAC) side effectsCJC-1295 (no DAC) mistakes to avoidCJC-1295 (no DAC) who should avoid itCJC-1295 (no DAC) half-lifeCJC-1295 (no DAC) how long to workCJC-1295 (no DAC) legal statusCJC-1295 (no DAC) how it workscjc 1295 vs tesamorelinipamorelin vs cjc 1295cjc 1295 vs sermorelinAsk the AI Coach
Last updated 2026-06-15.